The combined serum levels of miR-375 and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancer

International Journal of Cancer

Volumn 137, Issue 6, 2015, Pages 1406-1416

  Wach, Sven ^a   Al Janabi, Omar ^a   Weigelt, Katrin ^a   Fischer, Kersten ^b   Greither, Thomas ^b   Marcou, Marios ^b   Theil, Gerit ^b   Nolte, Elke ^a   Holzhausen, Hans Juergen ^b   Stöhr, Robert ^a   Huppert, Verena ^a   Hartmann, Arndt ^a   Fornara, Paolo ^b   Wullich, Bernd ^a   Taubert, Helge ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

diagnosis; disease specific survival; miR 375; overall survival; prostate cancer; urokinase plasminogen activator receptor

Indexed keywords

MICRORNA 375; UROKINASE RECEPTOR; MICRORNA; MIRN375 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; BLOOD; CASE CONTROL STUDY; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; RISK; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RISK; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84936846046     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29505     Document Type: Article

References (50)

1. Ferlay, J, Shin HR, Bray F, et al., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Kuner R, Brase JC, Sultmann H, et al., microRNA biomarkers in body fluids of prostate cancer patients. Methods 2013; 59: 132-7.
3. Liu W, Vivian CJ, Brinker AE, et al., Microenvironmental influences on metastasis suppressor expression and function during a metastatic cell's journey. Cancer Microenviron 2014; 7: 117-31 10.1007/s12307-014-0148-4.
4. Dimakakos A, Armakolas A, Koutsilieris M,. Novel tools for prostate cancer prognosis, diagnosis, and follow-up. Biomed Res Int 2014; 2014: 890697
5. Fang YX, Gao WQ,. Roles of microRNAs during prostatic tumorigenesis and tumor progression. Oncogene 2013;doi:10.1038/onc.2013.54.
6. Bok RA, Small EJ,. Bloodborne biomolecular markers in prostate cancer development and progression. Nat Rev Cancer 2002; 2: 918-26.
7. Beachy SH, Repasky EA,. Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update. Cancer Immunol Immunother 2008; 57: 759-75.
8. Shariat SF, Semjonow A, Lilja H, et al., Tumor markers in prostate cancer I: blood-based markers. Acta Oncol 2011; 50 (Suppl 1): 61-75.
9. Yan JW, Lin JS, He XX,. The emerging role of miR-375 in cancer. Int J Cancer 2014; 135: 1011-8.
10. Szczyrba J, Loprich E, Wach S, et al., The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res 2010; 8: 529-38.
11. Wach S, Nolte E, Szczyrba J, et al., MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int J Cancer 2012; 130: 611-21.
12. Schäfer A, Jung M, Mollenkopf HJ, et al., Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 2010; 126: 1166-76.
13. Nguyen HC, Xie W, Yang M, et al., Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate 2013; 73: 346-54.
14. Brase JC, Johannes M, Schlomm T, et al., Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 2011; 128: 608-16.
15. Selth LA, Townley S, Gillis JL, et al., Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int J Cancer 2012; 131: 652-61.
16. Cheng HH, Mitchell PS, Kroh EM, et al., Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of Cancer-associated hypoxia. PLoS One 2013; 8: e69239
17. Bryant RJ, Pawlowski T, Catto JW, et al., Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 2012; 106: 768-74.
18. Waltering KK, Porkka KP, Jalava SE, et al., Androgen regulation of micro-RNAs in prostate cancer. Prostate 2011; 71: 604-14.
19. Mahn R, Heukamp LC, Rogenhofer S, et al., Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 2011; 77: 1265 e9-16.
20. Chen ZH, Zhang GL, Li HR, et al., A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate 2012; 72: 1443-52.
21. Blasi F,. The urokinase receptor. A cell surface, regulated chemokine. APMIS 1999; 107: 96-101.
22. Duffy MJ,. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004; 10: 39-49.
23. Mekkawy AH, Pourgholami MH, Morris DL,. Involvement of urokinase-type plasminogen activator system in cancer: an overview. Med Res Rev 2014; 34: 918-56.
24. Al-Janabi O, Taubert H, Lohse-Fischer A, et al., Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancer. Biomed Res Int 2014; 2014: 972587
25. Miyake H, Hara I, Yamanaka K, et al., Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 1999; 39: 123-9.
26. Almasi CE, Brasso K, Iversen P, et al., Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer. Prostate 2011; 71: 899-907.
27. Shariat SF, Roehrborn CG, McConnell JD, et al., Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 2007; 25: 349-55.
28. Schmittgen TD, Livak KJ,. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3: 1101-8.
29. Piironen T, Haese A, Huland H, et al., Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum. Clin Chem 2006; 52: 838-44.
30. Thomas C, Wiesner C, Melchior SW, et al., Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer. BJU Int 2009; 104: 29-34.
31. Huang X, Yuan T, Liang M, et al., Exosomal miR-1290 and miR-375 as prognostic markers in Castration-resistant prostate cancer. Eur Urol 2014;doi:10.1016/j.eururo.2014.07.035.
32. Dai X, Chiang Y, Wang Z, et al., Expression levels of microRNA-375 in colorectal carcinoma. Mol Med Rep 2012; 5: 1299-304.
33. Li Y, Jiang Q, Xia N, et al., Decreased expression of microRNA-375 in nonsmall cell lung cancer and its clinical significance. J Int Med Res 2012; 40: 1662-9.
34. Bierkens M, Krijgsman O, Wilting SM, et al., Focal aberrations indicate EYA2 and hsa-miR-375 as oncogene and tumor suppressor in cervical carcinogenesis. Genes Chromosomes Cancer 2013; 52: 56-68.
35. Chen Z, Saad R, Jia P, et al., Gastric adenocarcinoma has a unique microRNA signature not present in esophageal adenocarcinoma. Cancer 2013; 119: 1985-93.
36. Shen Y, Wang P, Li Y, et al., miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer. Br J Cancer 2013; 109: 92-9.
37. Wang Z, Hong Z, Gao F, et al., Upregulation of microRNA-375 is associated with poor prognosis in pediatric acute myeloid leukemia. Mol Cell Biochem 2013; 383: 59-65.
38. Kinoshita T, Hanazawa T, Nohata N, et al., The functional significance of microRNA-375 in human squamous cell carcinoma: aberrant expression and effects on cancer pathways. J Hum Genet 2012; 57: 556-63.
39. Dettmer M, Perren A, Moch H, et al., Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma. Thyroid 2013; 23: 1383-9.
40. de Souza Rocha Simonini P, Breiling A, Gupta N, et al., Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res 2010; 70: 9175-84.
41. Skog J, Wurdinger T, van Rijn S, et al., Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008; 10: 1470-6.
42. Huang X, Liang M, Dittmar R, et al., Extracellular MicroRNAs in urologic malignancies: chances and challenges. Int J Mol Sci 2013; 14: 14785-99.
43. Madhavan B, Yue S, Galli U, et al., Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity. Int J Cancer 2014;doi:10.1002/ijc.29324.
44. Tiryakioglu D, Bilgin E, Holdenrieder S, et al., miR-141 and miR-375 induction and release are different from PSA mRNA and PCA3 upon androgen stimulation of LNCaP cells. Biomed Rep 2013; 1: 802-6.
45. Szczyrba J, Nolte E, Wach S, et al., Downregulation of Sec23A protein by miRNA-375 in prostate carcinoma. Mol Cancer Res 2011; 9: 791-800.
46. Korpal M, Ell BJ, Buffa FM, et al., Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med 2011; 17: 1101-8.
47. Poy MN, Hausser J, Trajkovski M, et al., miR-375 maintains normal pancreatic alpha- and beta-cell mass. Proc Natl Acad Sci U S A 2009; 106: 5813-8.
48. El Ouaamari A, Baroukh N, Martens GA, et al., miR-375 targets 3'-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic beta-cells. Diabetes 2008; 57: 2708-17.
49. Heidegger I, Ofer P, Doppler W, et al., Diverse functions of IGF/insulin signaling in malignant and noncancerous prostate cells: proliferation in cancer cells and differentiation in noncancerous cells. Endocrinology 2012; 153: 4633-43.
50. Cao Y, Lindstrom S, Schumacher F, et al., Insulin-like growth factor pathway genetic polymorphisms, circulating IGF1 and IGFBP3, and prostate cancer survival. Cancer Inst 2014; 106: dju085.